Placebo interventions for all clinical conditions

Asbjørn Hróbjartsson, Peter C Gøtzsche, Asbjørn Hróbjartsson, Peter C Gøtzsche

Abstract

Background: Placebo interventions are often claimed to substantially improve patient-reported and observer-reported outcomes in many clinical conditions, but most reports on effects of placebos are based on studies that have not randomised patients to placebo or no treatment. Two previous versions of this review from 2001 and 2004 found that placebo interventions in general did not have clinically important effects, but that there were possible beneficial effects on patient-reported outcomes, especially pain. Since then several relevant trials have been published.

Objectives: Our primary aims were to assess the effect of placebo interventions in general across all clinical conditions, and to investigate the effects of placebo interventions on specific clinical conditions. Our secondary aims were to assess whether the effect of placebo treatments differed for patient-reported and observer-reported outcomes, and to explore other reasons for variations in effect.

Search strategy: We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library Issue 4, 2007), MEDLINE (1966 to March 2008), EMBASE (1980 to March 2008), PsycINFO (1887 to March 2008) and Biological Abstracts (1986 to March 2008). We contacted experts on placebo research, and read references in the included trials.

Selection criteria: We included randomised placebo trials with a no-treatment control group investigating any health problem.

Data collection and analysis: Two authors independently assessed trial quality and extracted data. We contacted study authors for additional information. Trials with binary data were summarised using relative risk (a value of less than 1 indicates a beneficial effect of placebo), and trials with continuous outcomes were summarised using standardised mean difference (a negative value indicates a beneficial effect of placebo).

Main results: Outcome data were available in 202 out of 234 included trials, investigating 60 clinical conditions. We regarded the risk of bias as low in only 16 trials (8%), five of which had binary outcomes.In 44 studies with binary outcomes (6041 patients), there was moderate heterogeneity (P < 0.001; I(2) 45%) but no clear difference in effects between small and large trials (symmetrical funnel plot). The overall pooled effect of placebo was a relative risk of 0.93 (95% confidence interval (CI) 0.88 to 0.99). The pooled relative risk for patient-reported outcomes was 0.93 (95% CI 0.86 to 1.00) and for observer-reported outcomes 0.93 (95% CI 0.85 to 1.02). We found no statistically significant effect of placebo interventions in four clinical conditions that had been investigated in three trials or more: pain, nausea, smoking, and depression, but confidence intervals were wide. The effect on pain varied considerably, even among trials with low risk of bias.In 158 trials with continuous outcomes (10,525 patients), there was moderate heterogeneity (P < 0.001; I(2) 42%), and considerable variation in effects between small and large trials (asymmetrical funnel plot). It is therefore a questionable procedure to pool all the trials, and we did so mainly as a basis for exploring causes for heterogeneity. We found an overall effect of placebo treatments, standardised mean difference (SMD) -0.23 (95% CI -0.28 to -0.17). The SMD for patient-reported outcomes was -0.26 (95% CI -0.32 to -0.19), and for observer-reported outcomes, SMD -0.13 (95% CI -0.24 to -0.02). We found an effect on pain, SMD -0.28 (95% CI -0.36 to -0.19)); nausea, SMD -0.25 (-0.46 to -0.04)), asthma (-0.35 (-0.70 to -0.01)), and phobia (SMD -0.63 (95% CI -1.17 to -0.08)). The effect on pain was very variable, also among trials with low risk of bias. Four similarly-designed acupuncture trials conducted by an overlapping group of authors reported large effects (SMD -0.68 (-0.85 to -0.50)) whereas three other pain trials reported low or no effect (SMD -0.13 (-0.28 to 0.03)). The pooled effect on nausea was small, but consistent. The effects on phobia and asthma were very uncertain due to high risk of bias. There was no statistically significant effect of placebo interventions in the seven other clinical conditions investigated in three trials or more: smoking, dementia, depression, obesity, hypertension, insomnia and anxiety, but confidence intervals were wide.Meta-regression analyses showed that larger effects of placebo interventions were associated with physical placebo interventions (e.g. sham acupuncture), patient-involved outcomes (patient-reported outcomes and observer-reported outcomes involving patient cooperation), small trials, and trials with the explicit purpose of studying placebo. Larger effects of placebo were also found in trials that did not inform patients about the possible placebo intervention.

Authors' conclusions: We did not find that placebo interventions have important clinical effects in general. However, in certain settings placebo interventions can influence patient-reported outcomes, especially pain and nausea, though it is difficult to distinguish patient-reported effects of placebo from biased reporting. The effect on pain varied, even among trials with low risk of bias, from negligible to clinically important. Variations in the effect of placebo were partly explained by variations in how trials were conducted and how patients were informed.

Conflict of interest statement

None known.

Figures

1
1
Methodological quality summary: review authors' judgments about each methodological quality item for each included study.
2
2
Methodological quality graph: review authors' judgments about each methodological quality item presented as percentages across all included studies.
3
3
Funnel plot of comparison: 1 Main analysis: overall pooled analyses, outcome: 1.1 Binary outcomes.
4
4
Funnel plot of comparison: 1 Main analysis: overall pooled analyses, outcome: 1.2 Continuous outcomes.
1.1. Analysis
1.1. Analysis
Comparison 1 Main analysis: overall pooled analyses, Outcome 1 Binary outcomes.
1.2. Analysis
1.2. Analysis
Comparison 1 Main analysis: overall pooled analyses, Outcome 2 Continuous outcomes.
2.1. Analysis
2.1. Analysis
Comparison 2 Main analysis: patient‐reported or observer‐reported outcomes, Outcome 1 Patient‐reported binary outcomes.
2.2. Analysis
2.2. Analysis
Comparison 2 Main analysis: patient‐reported or observer‐reported outcomes, Outcome 2 Observer‐reported binary outcomes.
2.3. Analysis
2.3. Analysis
Comparison 2 Main analysis: patient‐reported or observer‐reported outcomes, Outcome 3 Patient‐reported continuous outcomes.
2.4. Analysis
2.4. Analysis
Comparison 2 Main analysis: patient‐reported or observer‐reported outcomes, Outcome 4 Observer‐reported continuous outcomes.
3.1. Analysis
3.1. Analysis
Comparison 3 Main analysis: clinical conditions investigated in three trials or more, Outcome 1 Binary outcomes.
3.2. Analysis
3.2. Analysis
Comparison 3 Main analysis: clinical conditions investigated in three trials or more, Outcome 2 Continuous outcomes.
4.1. Analysis
4.1. Analysis
Comparison 4 Supplementary analysis: adverse effects, Outcome 1 Binary outcomes.
4.2. Analysis
4.2. Analysis
Comparison 4 Supplementary analysis: adverse effects, Outcome 2 Continuous outcomes.
5.1. Analysis
5.1. Analysis
Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 1 Patient‐reported outcomes that are non‐observable.
5.2. Analysis
5.2. Analysis
Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 2 Patient‐reported outcomes that are observable.
5.3. Analysis
5.3. Analysis
Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 3 Observer‐reported outcomes involving patient's cooperation.
5.4. Analysis
5.4. Analysis
Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 4 Observer‐reported outcomes not involving patient's cooperation.
5.5. Analysis
5.5. Analysis
Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 5 Laboratory outcomes.
5.6. Analysis
5.6. Analysis
Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 6 Patient‐reported outcomes that are non‐observable.
5.7. Analysis
5.7. Analysis
Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 7 Patient‐reported outcomes that are observable.
5.8. Analysis
5.8. Analysis
Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 8 Observer‐reported outcomes involving patient's cooperation.
5.9. Analysis
5.9. Analysis
Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 9 Observer‐reported outcomes not involving patient's cooperation.
5.10. Analysis
5.10. Analysis
Comparison 5 Effect modification subgroup analysis: type of outcomes, Outcome 10 Laboratory outcomes.
6.1. Analysis
6.1. Analysis
Comparison 6 Effect modification subgroup analysis: the purpose of the trials, Outcome 1 To study the effect of placebo was an explicit trial purpose.
6.2. Analysis
6.2. Analysis
Comparison 6 Effect modification subgroup analysis: the purpose of the trials, Outcome 2 To study the effect of placebo was not an explicit trial purpose.
6.3. Analysis
6.3. Analysis
Comparison 6 Effect modification subgroup analysis: the purpose of the trials, Outcome 3 To study the effect of placebo was an explicit trial purpose.
6.4. Analysis
6.4. Analysis
Comparison 6 Effect modification subgroup analysis: the purpose of the trials, Outcome 4 To study the effect of placebo was not an explicit trial purpose.
7.1. Analysis
7.1. Analysis
Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 1 Psychological placebos.
7.2. Analysis
7.2. Analysis
Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 2 Physical placebos.
7.3. Analysis
7.3. Analysis
Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 3 Pharmacological placebos.
7.4. Analysis
7.4. Analysis
Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 4 Psychological placebos.
7.5. Analysis
7.5. Analysis
Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 5 Physical placebos.
7.6. Analysis
7.6. Analysis
Comparison 7 Effect modification subgroup analysis: type of placebo interventions, Outcome 6 Pharmacological placebos.
8.1. Analysis
8.1. Analysis
Comparison 8 Effect modification subgroup analysis: patient information, Outcome 1 Binary outcomes: patients not informed that the trial involved placebo.
8.2. Analysis
8.2. Analysis
Comparison 8 Effect modification subgroup analysis: patient information, Outcome 2 Binary outcomes: patients informed that the trial involved placebo (or not stated).
8.3. Analysis
8.3. Analysis
Comparison 8 Effect modification subgroup analysis: patient information, Outcome 3 Continuous outcomes: patients not informed that the trial involved placebo.
8.4. Analysis
8.4. Analysis
Comparison 8 Effect modification subgroup analysis: patient information, Outcome 4 Continuous outcomes: patients informed that the trial involved placebo (or not stated).
9.1. Analysis
9.1. Analysis
Comparison 9 Effect modification subgroup analysis: placebo as add‐on treatment, Outcome 1 Add‐on treatment: yes.
9.2. Analysis
9.2. Analysis
Comparison 9 Effect modification subgroup analysis: placebo as add‐on treatment, Outcome 2 Add‐on treatment: no or not stated.
9.3. Analysis
9.3. Analysis
Comparison 9 Effect modification subgroup analysis: placebo as add‐on treatment, Outcome 3 Add‐on treatment: yes.
9.4. Analysis
9.4. Analysis
Comparison 9 Effect modification subgroup analysis: placebo as add‐on treatment, Outcome 4 Add‐on treatment: no or not stated.
10.1. Analysis
10.1. Analysis
Comparison 10 Risk of bias subgroup analysis: blinding of placebo treatment providers, Outcome 1 Placebo intervention provider blinded: yes.
10.2. Analysis
10.2. Analysis
Comparison 10 Risk of bias subgroup analysis: blinding of placebo treatment providers, Outcome 2 Placebo intervention provider blinded: no or not stated.
10.3. Analysis
10.3. Analysis
Comparison 10 Risk of bias subgroup analysis: blinding of placebo treatment providers, Outcome 3 Placebo intervention provider blinded: yes.
10.4. Analysis
10.4. Analysis
Comparison 10 Risk of bias subgroup analysis: blinding of placebo treatment providers, Outcome 4 Placebo intervention provider blinded: no or not stated.
11.1. Analysis
11.1. Analysis
Comparison 11 Risk of bias subgroup analysis: blinding of observer, Outcome 1 Blinding of observer: yes.
11.2. Analysis
11.2. Analysis
Comparison 11 Risk of bias subgroup analysis: blinding of observer, Outcome 2 Blinding of observer: not stated.
11.3. Analysis
11.3. Analysis
Comparison 11 Risk of bias subgroup analysis: blinding of observer, Outcome 3 Blinding of observer: yes.
11.4. Analysis
11.4. Analysis
Comparison 11 Risk of bias subgroup analysis: blinding of observer, Outcome 4 Blinding of observer: not stated.
12.1. Analysis
12.1. Analysis
Comparison 12 Risk of bias subgroup analysis: variance inequality and skewness, Outcome 1 No signs of unequal variance or skewness.
12.2. Analysis
12.2. Analysis
Comparison 12 Risk of bias subgroup analysis: variance inequality and skewness, Outcome 2 Signs of either unequal variance or skewness.
13.1. Analysis
13.1. Analysis
Comparison 13 Risk of bias subgroup analysis: selection of outcome, Outcome 1 Selection of outcome: primary trial outcome clearly indicated.
13.2. Analysis
13.2. Analysis
Comparison 13 Risk of bias subgroup analysis: selection of outcome, Outcome 2 Selection of outcome: primary trial outcome not clearly indicated (or not selected).
13.3. Analysis
13.3. Analysis
Comparison 13 Risk of bias subgroup analysis: selection of outcome, Outcome 3 Selection of outcome: primary trial outcome clearly indicated.
13.4. Analysis
13.4. Analysis
Comparison 13 Risk of bias subgroup analysis: selection of outcome, Outcome 4 Selection of outcome: primary trial outcome not clearly indicated (or not selected).
14.1. Analysis
14.1. Analysis
Comparison 14 Risk of bias subgroup analysis: format of outcome, Outcome 1 Outcome was final values.
14.2. Analysis
14.2. Analysis
Comparison 14 Risk of bias subgroup analysis: format of outcome, Outcome 2 Outcome was change from baseline.
15.1. Analysis
15.1. Analysis
Comparison 15 Risk of bias subgroup analysis: concealed allocation, Outcome 1 Concealed allocation adequate.
15.2. Analysis
15.2. Analysis
Comparison 15 Risk of bias subgroup analysis: concealed allocation, Outcome 2 Concealed allocation unclear.
15.3. Analysis
15.3. Analysis
Comparison 15 Risk of bias subgroup analysis: concealed allocation, Outcome 3 Concealed allocation adequate.
15.4. Analysis
15.4. Analysis
Comparison 15 Risk of bias subgroup analysis: concealed allocation, Outcome 4 Concealed allocation unclear.
16.1. Analysis
16.1. Analysis
Comparison 16 Risk of bias subgroup analysis: trial size, Outcome 1 Trial size >49.
16.2. Analysis
16.2. Analysis
Comparison 16 Risk of bias subgroup analysis: trial size, Outcome 2 Trial size 49 or less.
16.3. Analysis
16.3. Analysis
Comparison 16 Risk of bias subgroup analysis: trial size, Outcome 3 Trial size >49.
16.4. Analysis
16.4. Analysis
Comparison 16 Risk of bias subgroup analysis: trial size, Outcome 4 Trial size 49 or less.
17.1. Analysis
17.1. Analysis
Comparison 17 Risk of bias subgroup analysis: dropouts, Outcome 1 Dropout rates no more than 15%.
17.2. Analysis
17.2. Analysis
Comparison 17 Risk of bias subgroup analysis: dropouts, Outcome 2 Dropout rates >15%, or not stated.
17.3. Analysis
17.3. Analysis
Comparison 17 Risk of bias subgroup analysis: dropouts, Outcome 3 Dropout rates no more than 15%.
17.4. Analysis
17.4. Analysis
Comparison 17 Risk of bias subgroup analysis: dropouts, Outcome 4 Dropout rates > 15%, or not stated.
18.1. Analysis
18.1. Analysis
Comparison 18 Risk of bias subgroup analysis: clearly concealed allocation + trial size >49 + dropout max 15%, Outcome 1 Binary outcomes.
18.2. Analysis
18.2. Analysis
Comparison 18 Risk of bias subgroup analysis: clearly concealed allocation + trial size >49 + dropout max 15%, Outcome 2 Continuous outcomes.
18.3. Analysis
18.3. Analysis
Comparison 18 Risk of bias subgroup analysis: clearly concealed allocation + trial size >49 + dropout max 15%, Outcome 3 Pain heterogeneity.

Source: PubMed

3
Subscribe